1Winblad B, Palmer K, Kivipelto M, et al.Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.J Intern Med, 2004, 256: 240-246.
2Petersen R.Mild cognitive impairment as a diagnostic entity.J Intern Med,2004, 256: 183-194.
3Masters CL, Simms G, Weinman NA, et al.Amyloid plaque core protein in Alzheimer′s disease and Down syndrome.Proc Natl Acad Sci, 1985, 82: 4245-4249.
4Haas C, Selkoe DJ.Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide.Cell,1993, 75: 1039-1042.
5Lammich S, Kojro E, Postina R, et al.Constitutive and regulated alpha-secretase cleavage of Alzheimer′s amyloid precursor protein by a disintegrin metalloprotease.Proc Natl Acad Sci,1999,96: 3922-3927.
6Li YM, Xu M, Lai MT, et al.Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.Nature, 2000, 405: 689-694.
7Farlow M, Ghetti B, Benson MD, et al.Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer′s disease.Lancet, 1992, 340: 453-454.
9Andreasen N, Minthon L, Vanmechelen E, et al.CSF t-tau and CSF-Ab42 as predictors of development of Alzheimer′s disease in patients with mild cognitive impairment.Neurosci Lett,1999, 273: 5-8.
10Andreasen N, Minthon L, Davidsson P, et al.Evaluation of CSF-tau and CSFAb42 as diagnostic markers for Alzheimer′s disease in clinical practice.Arch Neurol ,2001, 58: 373-379.
